Natco to buy U.S. firm Dash in $18-mn deal

Drugmaker Natco Pharma is planning to acquire U.S. firm Dash Pharmaceuticals LLC, for a cash consideration of $18 million, through one of its subsidiaries. The acquisition, which is likely to be compl

Drugmaker Natco Pharma is planning to acquire U.S. firm Dash Pharmaceuticals LLC, for a cash consideration of $18 million, through one of its subsidiaries.

The acquisition, which is likely to be completed by January, will provide a front-end to engage with its customers directly in the U.S., the largest pharmaceutical market in the world, Natco Pharma said on Tuesday.

In a filing with the stock exchange, following a meeting of the Board, Natco said it proposed to enter into an agreement to acquire 100% stake in Dash Pharmaceuticals. The transaction will be subject to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements.